Previously called STS101, the company said Wednesday that the drug’s brand name is Atzumi and is indicated for acute migraine ...

Atzumi combines a proprietary advanced powder and device technology to simplify nasal delivery of dihydroergotamine for acute treatment of migraine.

New York, April 30, 2025 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) applauds the U.S. Food and Drug Administration (FDA ... more about this approval in Johnson & Johnson’s news ...

The FDA is set to complete its review ... Massachusetts-based Abiomed Inc., a portfolio company of Johnson & Johnson. It was at Abiomed that he met Dr. Kolski, and they came up with the idea for a ...

Health care giantJohnson & Johnson said on Wednesday the US Food and Drug Administration (FDA) has approved its drug to treat patients aged 12 years and older with an immune-mediated disorder.

Johnson & Johnson (J&J) has received approval from the US Food and Drug Administration ... reduce levels of circulating immunoglobulin G antibodies that underlie gMG. The FDA’s decision on the drug ...

(RTTNews) - Johnson & Johnson (JNJ) announced the FDA has approved IMAAVY, a human FcRn-blocking monoclonal antibody, for the treatment of generalized myasthenia gravis. The approval is supported ...

New York, April 30, 2025 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) applauds the U.S. Food and Drug Administration (FDA) approval of IMAAVY ... Learn more about this approval in Johnson ...

New York, April 30, 2025 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) applauds the U.S. Food and Drug Administration (FDA) approval of IMAAVY ... Learn more about this approval in Johnson ...